Anthony Mancini Sells 1,774 Revolution Medicines (RVMD) Shares at $199.30 Each

Anthony Mancini sold 1,774 shares of Revolution Medicines, Inc. (RVMD) at $199.30 per share for a total of $353,449 on September 19, 2026.

Who is Anthony Mancini and what is his actual role at Revolution Medicines, Inc.?

The filed form simply states "See Remarks" for Anthony Mancini's position. This notation means the role details are included in the remarks section of the document, which is not reproduced here. In practice, individuals who file a Form 4 are typically executives (CEO, CFO, president) or board members, giving them direct access to the company's financial and strategic information.

Being listed as an insider implies that the individual is subject to the transparency obligations imposed by the Securities and Exchange Commission (SEC). Any transaction in the company's securities must be reported within two business days of the trade to ensure equal information access for all investors.

Transaction details: 1,774 shares at $199.30 each

On September 19, 2026, Anthony Mancini transferred ownership of 1,774 Revolution Medicines, Inc. shares at a per-share price of $199.30. The total value (1,774 × $199.30) amounts to $353,449, which appears in the form as the gross proceeds from the sale.

The stated price corresponds to the market value of the share on the transaction date, as quoted on the primary market where RVMD is listed. No other elements, such as a premium or discount, are mentioned in the form.

Why insiders sell their shares - possible reasons

Executives may decide to liquidate part of their holdings for various reasons. Portfolio diversification is a common motivation: holding a significant portion of one company exposes an individual to concentration risk that some executives seek to reduce.

Tax planning also plays a significant role. Selling shares can allow for the realization of taxable gains at a time when the taxpayer anticipates a more favorable tax bracket or to offset losses elsewhere in the portfolio.

Personal liquidity needs, such as funding real estate projects or paying family obligations, may justify a one-time sale. It's important to note that the decision to sell should not automatically be interpreted as a negative judgment on the company's prospects; it may reflect purely personal considerations or cash management decisions.

How individual investors track Form 4 filings

The SEC's EDGAR site provides free access to all Form 4 filings. Investors can search by the ticker RVMD or the insider's name. Once the document is opened, key fields (number of shares, price, date) are presented in a structured format, making data extraction straightforward.

Many financial services aggregate this information and present it as news feeds or tracking tables. Some free tools, such as online brokerage platforms, offer alerts when an executive makes a transaction, allowing individual investors to stay informed in real-time.

It's important to keep in mind the inherent limitations of this data. The Form 4 does not reveal the underlying motivations for the transaction or the company's internal plans. Investors should combine analysis of insider movements with other information sources, such as quarterly reports, press releases, and industry analyses, before making a buy or sell decision.

In summary, Anthony Mancini's sale of 1,774 shares, reported via Form 4 on September 19, 2026, constitutes a public event that market participants can monitor through tools provided by the SEC. Understanding the insider's role, accurately reading the transaction figures, and considering possible reasons for the sale enable individual investors to integrate this information into a broader analysis of Revolution Medicines, Inc.